glp-1 obesity drug market forecast 2030 Drugs Size to Hit USD 132.79 Bn by 2035 GLP-1 Receptor Agonists Obesity Drugs
Description
Much literature to date has focused on the risk for drug-induced acute pancreatitis attributed to hyperstimulation of acinar cells 14,15
2021: Higher-dose semaglutide (Wegovy) for chronic weight management
Researchers had one group of 14,665 participants taking GLP-1RAs matched to 14,665 participants taking SGLT2is
In addition, since the first evidence of a beneficial effect of GLP-1RAs in BAD treatment was not available until 2019, we notice that the prescriptions of GLP-1RAs up until this year were made for other indications than BAD in contrast to bile acid sequestrants
The ACCC declined to comment.
IQR, interquartile range
